The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...

Kardigan may have only launched last year, but it seems the cardiovascular-focused biotech is already eyeing the public markets. | Kardigan may have only launched last year, but it seems the ...

As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to ...

Olympus has signed a definitive agreement to acquire BioProtect for $270 million, adding biodegradable balloon spacer ...

Kura Oncology has published early data on darlifarnib in combination with Bristol Myers Squibb’s Krazati, linking the drug ...

As the FDA adjusts to life without Marty Makary, M.D., Fierce has learned that the numerous policy reforms he put in motion ...

The Big Pharma is paying up to $1.5 billion, split between an upfront fee and a milestone payment, to buy shingles vaccine ...

Faced with a future of evaporating Xtandi sales, Astellas has set out ambitions to license fresh assets while also continuing ...

Biogen axed an Ionis-partnered antisense oligonucleotide that targets LRRK2 last year. Other biotechs continue to work on the ...

One day in early May, web-based prediction market platform Kalshi listed two contracts tied to Compass Pathways’ psilocybin ...

Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it acquired from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol ...

Though the results show competitive efficacy and tolerability, they may leave some observers slightly underwhelmed based on ...